Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die
Datenschutzhinweise)
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Leider können wir deine Anfrage auf diesem Weg nicht entgegennehmen. Bitte schreibe uns an: portal.support@ariva.de
Termine
Keine Termine bekannt.
Prognose & Kursziel
Keine aktuellen Prognosen oder Kursziele bekannt.
Stammdaten
Aktientyp
Stammaktie
Community-Beiträge zu Arrayit
Community-Beiträge
Aktuellste Threads
Boersi_
...bin gespannt, wie es hier weiter geht
Interessant sind u. a. auch deren tägliche Twitter-Meldungen:
https://twitter.com/arrayit
Boersi_
ARRAYIT Corp.
Arrayit hebt gerade ab...
News von heute:
Arrayit Corporation Awards $3M Stock Dividend to ARYC Shareholders
SUNNYVALE, CA / ACCESSWIRE / September 30, 2015 / Arrayit Corporation (OTCQB: ARYC), a life sciences company, announces today that the Arrayit Board of Directors has voted unanimously to issue 10,000,000 common shares of its subsidiary Avant Diagnostics (OTCQB: AVDX) to ARYC common shareholders, representing a present market value of approximately 3 million dollars. The 10,000,000 share AVDX dividend will be distributed on a pro rata basis to all ARYC shareholders of record as of the close of market today. Based on the approximately 450,000,000 common shares of ARYC currently issued, ARYC shareholders will receive approximately 0.022 shares of AVDX per share of ARYC. The company expects that the stock certificates can be distributed within approximately four weeks after September 30, 2015, pending regulatory approval of the transaction.
Arrayit's patented and proprietary microarray platform empowers scientists and doctors to decipher the human genome and proteome, elucidate pathways for major human illnesses, discover safer and more efficacious medicines, and develop methods to detect food-borne pathogens to enhance food safety. The company has leveraged its platform to develop the OvaDx(R) Pre-Symptomatic Ovarian Cancer Test as an aid to monitor women diagnosed with ovarian cancer. OvaDx(R) is a proteomic microarray that detects ovarian cancer auto-antibodies present in patient sera with high sensitivity and specificity. OvaDx(R) will be marketed and sold by Avant Diagnostics upon 510(k) FDA approval.
Arrayit CEO Rene Schena states, "We are delighted to offer a significant stock dividend to shareholders of Arrayit common stock. We appreciate all of our investors who share a vision for innovation and growth based on Arrayit's foundational technology. Through this dividend, it is our intent to showcase the exciting opportunity to own shares of Arrayit Corporation and Avant Diagnostics, Inc."
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.